Since the beginning of 2021, all the major economies are ramping up their vaccination campaigns, pinning their hopes of a swift recovery on the success of the newly developed COVID-19 vaccines. Recent researches conducted in UK and Israel suggested that the Pfizer/BioNTech and Oxford/AstraZeneca vaccines are effective in protecting against symptomatic infections. Moreover, in a briefing published by last week, the U.S. Food and Drug Administration has found the single-shot Johnson & Johnson coronavirus vaccine is safe and effective, potentially paving the way for its approval for emergency use. Johnson & Johnson has agreed to provide the US with 100 million doses by the end of June. The UK, EU and Canada have also ordered doses and 500 million doses have also been ordered through the COVAX scheme to supply poorer nations.
At a recent virtual meeting, the G7 leaders pledged to spend over $4.3 billion to develop and distribute effective tests, treatments, and vaccines around the world. Canada, France, Norway and the European Union further committed to donating additional vaccine doses with developing countries, so to increase the volume of vaccines available worldwide and support rapid reduction of virus transmission amongst some of the world’s most vulnerable and exposed populations.
At a recent virtual meeting, the G7 leaders pledged to spend over $4.3 billion to develop and distribute effective tests, treatments, and vaccines around the world. Canada, France, Norway and the European Union further committed to donating additional vaccine doses with developing countries, so to increase the volume of vaccines available worldwide and support rapid reduction of virus transmission amongst some of the world’s most vulnerable and exposed populations.
Related Articles
Nothing found.